Overall survival in the ITT population and by subgroup. a Kaplan-Meier... | Download Scientific Diagram
Lead team presentation
Comparative effectiveness of first line palbociclib plus letrozole vs. letrozole alone for hormone-receptor positive metastatic breast cancer in real world clinical practice - BJMO
2021 Update on Systemic Therapy for Breast Cancer | Published in healthbook TIMES Oncology Hematology
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Japanese patients in PALOMA-2: swimmer plot of subsequent therapy in... | Download Scientific Diagram
AGO_2022E_18_Endocrine Therapy of Metastatic Breast Cancer_MASTER_schwarz_final
PALOMA-2: Final OS - Slideset Download - Clinical Oncology 2022 | CCO
PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3 -
![ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR](https://cdn.koreabiomed.com/news/photo/202206/13831_14395_1052.jpg "ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR")
ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib | npj Precision Oncology
Final analysis of progression-free survival in the PALOMA-3 study... | Download Scientific Diagram
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer | PLOS ONE
Effectiveness and safety of Palbociclib as first-line treatment in advanced breast cancer - ILAPHAR | Revista de la OFIL
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer - Gelmon - 2020 - The Breast Journal -
Ribociclib Improves Survival in Advanced Breast Cancer - NCI
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - ScienceDirect
Lead team presentation
Progression-free survival (PFS) in the PALOMA-1 phase II trial... | Download Scientific Diagram
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer - Gelmon - 2020 - The Breast Journal -
